Ftse Mib
33.082,62
-0,26%
DAX
19.261,75
-0,22%
S&P 500
5.998,74
-0,38%
NASDAQ
19.060,48
-0,60%
Bitcoin
96.476,80
4,90%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cellectis SA (CLLS) Cellectis SA (CLLS) Notizie

Cellectis SA

CLLS
2,13
-0,01 (-0,47%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 22:06:46
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
05/11/202422:30GLOBECellectis Presents Multiple Strategies to Enhance CAR T-cell..
04/11/202422:30GLOBECellectis Provides Business Updates and Financial Results..
30/10/202421:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202421:30GLOBECellectis to Report Third Quarter 2024 Financial Results on..
22/10/202408:00GLOBECellectis to Present Data on TALE-Base Editors and Non-Viral..
11/9/202422:30EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
03/9/202422:30GLOBECellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells..
26/8/202422:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/8/202422:30GLOBECellectis Publishes a Molecular Therapy Article on a SMART..
07/8/202412:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/8/202408:00GLOBECellectis Appoints Dr. Adrian Kilcoyne as Chief Medical..
06/8/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/8/202422:30GLOBECellectis Provides Financial Results for the Second Quarter..
01/8/202422:30GLOBEFDA Grants Orphan Drug Designation to Cellectis’ CLLS52..
25/7/202422:30GLOBEFDA Grants Orphan Drug and Rare Pediatric Disease..
28/6/202422:30GLOBECellectis Reports Results from Shareholders Meeting Held on..
20/6/202422:30GLOBECellectis Publishes a Scientific Article Unveiling Three Key..
12/6/202422:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/6/202422:30GLOBECellectis Unveils a Non-Viral Gene Therapy Approach for..
04/6/202422:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/6/202422:30GLOBECellectis Receives Orphan Drug Designation for UCART22, its..
29/5/202422:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/5/202422:30GLOBECellectis’ Annual Shareholders General Meeting to be Held on..
28/5/202422:30GLOBECellectis Reports Financial Results for First Quarter 2024
28/5/202412:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/5/202422:30GLOBECellectis to Report First Quarter 2024 Financial Results on..
24/5/202422:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/5/202412:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/5/202408:00GLOBECellectis Announces Completion of the Additional Equity..
02/5/202422:30GLOBECellectis Appoints Arthur Stril as Interim Chief Financial..
29/4/202422:46GLOBECellectis Reports Financial Results for the Fourth Quarter..
22/4/202422:30GLOBECellectis Presents Novel TALEN® Editing Processes Enabling..
10/4/202422:30GLOBECellectis Publishes a Novel Intronic Gene Editing Approach..
08/4/202422:30GLOBECellectis Announces Two Poster Presentations on Novel TALEN®..
16/1/202422:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/1/202422:30GLOBECellectis announces the drawdown of the second tranche of..
22/12/202322:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/12/202322:30GLOBECellectis Reports Results from Shareholders Meeting Held on..
22/12/202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
Apertura: 2,14 Min: 2,09 Max: 2,155
Chiusura: 2,14

La tua Cronologia

NASDAQ
CLLS
Cellectis
ASX
AVG
Australian Vintage
BIT
UB5M1Y
Unicredit Bank
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network